同期同胞HLA全相合与亲缘间单倍体相合异基因造血干细胞移植治疗恶性血液病对比观察

目的 比较同胞HLA全相合与亲缘间单倍体相合异基因造血干细胞移植(allo-HSCT)在恶性血液病治疗中的造血重建情况、移植相关并发症及临床疗效.方法 18例恶性血液病患者中,HLA同胞全相合9例、亲缘间单倍体相合9例,回顾性分析两组造血重建情况、移植相关并发症及临床疗效情况.结果 两组在造血重建、预处理相关毒性、急慢性移植物抗宿主病(GVHD)及临床疗效经改良预处理方案后无明显差异,但在移植过程中及术后、血制品的输注量、CMV感染率及真菌感染率发生方面,单倍体相合移植组明显高于同胞全相合组.结论 经改良预处理方案后同胞HLA全相合与亲缘间单倍体相合allo-HSCT在恶性血液病治疗方而临床疗效相近,亲缘间单倍体相合移植为恶性血液病治疗开辟了又一新途径,从根本上解决了供者来源问题.

Comparitive study between compatriots HLA in the same period and haploidentical family donor allogeneic peripheral blood stem cell transplantation for the treatment of hematologic malignancies

Objective To compare the clinical effect, hematopoietic reconstitution, and adverse effects of compatriots HLA in the same period with haploidentical allogeneic hematopoietic stem cell transplantation among relatives for treatment of haematological malignancies. Methods 9 patients of compatriots HLA and 9 patients of haptoidentical allogeneic were recruited. The clinical effect, hematopoietic reconstitution, and transplant-related adverse effects of the observation groups were retrospectively analyzed. Results There was no statistical difference between the clinical effect in two groups, hematopoietic reconstitution, pretreatment-related toxicity and acute and chronic GVHD. The infusion volume of blood products, CMV infection and fungal infection in haploidentical transplant group was higher than that in compatriots HLA group. Conclusion HLA haploidentical family donor transplantation is a good way to increase the source of donor for the treatment of haematological malignancies.